# Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer

> **NCT00275951** · PHASE2 · COMPLETED · sponsor: **National Taiwan University Hospital** · enrollment: 39 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Cetuximab Plus P-HDFL

## Key facts

- **NCT ID:** NCT00275951
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2012-11-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00275951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00275951, "Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00275951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*